Geriatric Medicine Division of Geriatric Medicine

Total Page:16

File Type:pdf, Size:1020Kb

Geriatric Medicine Division of Geriatric Medicine FALL 2018 | UPDATE IN | GERIATRIC MEDICINE DIVISION OF GERIATRIC MEDICINE GERIATRIC OF DIVISION Inside This Edition Message from the Chief 2 Geroscience: Frontiers in the Biology of Aging I am pleased to share our latest issue of Update in Geriatric Medicine, especially our excitement for a 3 New Model of Care Is major augmentation of our research through the creation of a new, focused geroscience initiative led Making a Difference in Osteoporosis Treatment by Toren Finkel, MD, PhD, one of the most distinguished scientists in the field of aging research. 4 UPMC Physician Resources Recruited from the National Institutes of Health in 2017, Dr. Finkel has assembled an impressive team Video Rounds of new investigators to join him. Based on the observation that age itself is the most important risk 5 New Meta-Analysis Shows factor in many diseases affecting our geriatric patients — and data revealing dramatic extension Effects of Interventions on Adverse Drug Reactions of both lifespan and healthspan in experimental models — the goal is to determine which of these experimental strategies might hold the most promise for application in humans. Several of our 6 Testing New Models of Care for Chronic Low Division faculty already are collaborating in this enormous effort. Back Pain 8 Brain Amyloid Deposition Also in this issue of Update in Geriatric Medicine, we showcase new research findings from and the Cognition-Mobility Interface Susan Greenspan, MD, in preventing recurrent hip fractures; an important new initiative in chronic low back pain by Debra Weiner, MD; and new findings fromNeelesh Nadkarni, MD, PhD, on the 10 Welcome New Faculty role of brain amyloid in gait abnormalities. 11 Recent Publications Awards and We also are proud to share news of several recent awards bestowed on faculty members, recent Accomplishments published research from the Division, and the arrival of three talented, new faculty members. Finally, we celebrate the accomplishments of Joe Hanlon, PharmD, MS, whose internationally- recognized contributions have added immeasurably to our understanding of the role and risks of medications in the care of geriatric patients. With kind regards, Neil M. Resnick, MD Division Chief and Thomas Detre Professor of Medicine Associate Director, Aging Institute of UPMC Senior Services and the University of Pittsburgh Director, Hartford Center of Excellence in Geriatrics Affiliated with the University of Pittsburgh School of Medicine, UPMC Presbyterian Shadyside is ranked among America’s Best Hospitals by U.S. News & World Report. Geroscience: Frontiers in the Biology of Aging Can we discover and understand the basic biological mechanisms and pathways that regulate the aging process? Moreover, by fundamentally understanding how and why processes of aging occur, can we devise the tools and technologies that will allow us to intervene, modulate, or perhaps reverse the full range of age-related diseases and disabilities that occur as consequence of the biology of aging? This is the field of geroscience, and UPMC issues, and a host of quality control in a position to develop new drugs that and the University of Pittsburgh are investing mechanisms can go awry as individuals’ can regulate those mechanistic processes, heavily in the pursuit of answers that will age. Yes, there are multiple aspects or leading to effective treatments for a wide unlock the mysteries and complex processes hallmarks of aging, and it’s certainly range of age-related diseases. These studies of how and why human beings age, and complex, “But that is not to say these will “lead to new approaches and new ultimately how we can intervene to more processes are not regulated or cannot in classes of medicines that we think will effectively improve and extend one’s quality some sense be malleable to interventions improve the quality of people’s lives,” of life for as long as possible. on the cellular or molecular level. We know, says Dr. Finkel. for example, in simple organisms that Helping to lead these emerging efforts in modifications to certain genes or proteins geroscience is Toren Finkel, MD, PhD, A Translational Approach to can have profound effects on both lifespan director of the Aging Institute, professor of Modifying Aging Processes and health span. Similar modifications are medicine in the Division of Cardiology, and Driving Disease what we hope to accomplish with human | 2 UPDATE IN GERIATRIC MEDICINE | the G. Nicholas Beckwith III and Dorothy B. aging and age-related conditions such as Cardiovascular disease, cancer, neuro- Beckwith chair in translational medicine. Alzheimer’s disease,” says Dr. Frankel. degen erative diseases — these all have a Dr. Finkel arrived at the University of powerful age-related component. Until Pittsburgh and UPMC in June 2017 after Fundamentally, Dr. Finkel and the groups now, most of the strategies for treating a distinguished 25-year career with the working on these problems believe that these broad categories of illness have been National Institutes of Health, where he was once we more fully understand the basic very disease-specific with some successes the chief of the Center for Molecular mechanisms that drive aging, we will be and equivalent number of failures. The Medicine in the National Heart, Lung, and approach that Dr. Finkel and colleagues Blood Institute (NHLBI) immedi ately are taking — the geroscience approach — preceding his arrival in Pittsburgh. means that, “We are not necessarily looking “The support and commitment from both for or hoping to develop disease-specific the University of Pittsburgh and UPMC to therapies per se. We are interested in the grow into one of the premier basic biology molecules and processes that underlie the of aging and translational research centers biology of aging, which, if we can intervene in the world was what really attracted me to in, we think will prevent these sorts of come to Pittsburgh — to pursue my own illnesses from happening in the first place,” research in the biology of aging front but says Dr. Finkel. also to help lead this effort with so many The Aging Institute, which Dr. Finkel now dedicated faculty across many disciplines,” leads, has begun to expand its research focus says Dr. Finkel. and capabilities to pursue many avenues of basic and translational research with respect Understanding and Modifying “ We are not necessarily to the goals of geroscience writ large. the Basic Biology and Pathways looking for or hoping to “In the end, we will have approximately 15 of Aging develop disease-specific different laboratories all working on various therapies per se. We We know much about the basic biology aspects of aging biology, so the work here are interested in the of aging and its pathways, but significant will be incredibly diverse. Coupled with the molecules and processes gaps remain to be explored and understood. basic science labs will be a high throughput that underlie the biology At the molecular level, it is known that screening facility that will help significantly of aging, which, if we can accumulated nuclear DNA damage, in our mission to develop entirely new intervene in, we think will shor tening of the telomeres, problems classes of anti-aging drugs. We also hope prevent these sorts of with mitochondria, protein aggregation illnesses from happening Continued on Page 10 in the first place.” Toren Finkel, MD, PhD FALL 2018 New Model of Care Is Making a Difference in Osteoporosis Treatment The risk of osteoporotic fractures in adults over the age of 50 remains significantly high. For women, 50 percent will sustain an osteoporotic fracture sometime during their life. Twenty-five percent of men will experience a fracture. These individuals also are at significant risk (more than two-fold) for a second fracture and concomitant morbidity and mortality. “Generally speaking, we’re grossly under- scan and appropriate lab testing. The results treating individuals hospitalized with of these tests and their implications are osteoporotic fractures. Only about carefully reviewed with the patients to 20 percent of people are treated, and ensure they adequately comprehend the that is simply far too few. The reasons are information. Treatment options are recom - many, but probably the largest problem we mended and discussed, medications are facing is a breakdown in communication prescribed if necessary, and direct follow- between providers coupled with the fact ups with patients occur several months | 3 DIVISION OF GERIATRIC MEDICINE | that the majority of these individuals have after the initial visit. “We discuss fall other serious health conditions that may prevention and strategies at home to take priority in their primary care,” says decrease that risk. If they smoke, we talk Susan L. Greenspan, MD. about its impact on bone density and the various cessation programs available. Dr. Greenspan is dually trained in geriatrics I explain the vital importance of calcium and endocrinology, and currently serves and vitamin D. Patients have my contact as director of the UPMC Osteoporosis information, along with an education Prevention and Treatment Center, director packet so they can call me directly with of the Bone Health Program at UPMC any questions or concerns once they Magee-Womens Hospital, and as principal leave,” says Karen Vujevich, MSN, CRNP, investigator of both the Pittsburgh Claude who is the fracture liaison coordinator at D. Pepper Older Americans Independence UPMC working alongside Dr. Greenspan. “ Generally speaking, we’re grossly Center and the Division’s NIH-funded Importantly, all of this is communicated under treating individuals with T32 Program in Research Training in to the patient’s primary care provider osteoporotic fractures. Only about geriatrics. Dr. Greenspan’s research focus for continuity of care and follow-up. 20 percent of people are treated, encompasses the pathophysiology, and that is simply far too few. ” evaluation, and treatment of osteoporosis. FLS Program Shows Susan L. Greenspan, MD In 2014, Dr. Greenspan and the Division of Positive Results in Newly Geriatric Medicine piloted a Fracture Liaison Published Findings Service (FLS) as part of a combined quality improvement (QI) study with two other In February 2018, Dr.
Recommended publications
  • In Vitrocharacterization of Pittsburgh Compound-B Binding to Lewy Bodies
    The Journal of Neuroscience, September 26, 2007 • 27(39):10365–10371 • 10365 Neurobiology of Disease In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies Michelle T. Fodero-Tavoletti,1,2,4 David P. Smith,1,4 Catriona A. McLean,5 Paul A. Adlard,4 Kevin J. Barnham,1,2,4 Lisa E. Foster,1 Laura Leone,1 Keyla Perez,1,2,4 Mikhalina Corte´s,4 Janetta G. Culvenor,1,3,4 Qiao-Xin Li,1,4 Katrina M. Laughton,1,4 Christopher C. Rowe,6 Colin L. Masters,1,4 Roberto Cappai,1,2,4 and Victor L. Villemagne1,4,6 1Department of Pathology, 2Bio21 Institute, and 3Centre for Neuroscience, The University of Melbourne, Melbourne, Victoria 3010, Australia, 4The Mental Health Research Institute of Victoria, Parkville, Victoria 3052, Australia, 5Department of Anatomical Pathology, Alfred Hospital, Prahran, Victoria 3181, Australia, and 6Centre for PET, Austin Hospital, Heidelberg, Victoria 3084, Australia Dementia with Lewy bodies (DLB) is pathologically characterized by the presence of ␣-synuclein-containing Lewy bodies within the neocortical, limbic, and paralimbic regions. Like Alzheimer’s disease (AD), A␤ plaques are also present in most DLB cases. The contri- bution of A␤ to the development of DLB is unclear. [ 11C]-Pittsburgh compound B ([ 11C]-PIB) is a thioflavin-T derivative that has allowed in vivo A␤ burden to be quantified using positron emission tomography (PET). [ 11C]-PIB PET studies have shown similar high cortical [ 11C]-PIB binding in AD and DLB subjects. To establish the potential binding of PIB to ␣-synuclein in DLB patients, we characterized the in vitro binding of PIB to recombinant human ␣-synuclein and DLB brain homogenates.
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Molecular Imaging in Alzheimer's Disease
    CORE Metadata, citation and similar papers at core.ac.uk Provided by PubMed Central Nordberg Alzheimer’s Research & Therapy 2011, 3:34 http://alzres.com/content/3/6/34 REVIEW Molecular imaging in Alzheimer’s disease: new perspectives on biomarkers for early diagnosis and drug development Agneta Nordberg* Introduction Abstract Alzheimer’s disease (AD) is characterized by a slow Recent progress in molecular imaging has provided continued deterioration of cognitive processes. Th e fi rst new important knowledge for further understanding symptoms of episodic memory disturbances might be the time course of early pathological disease processes quite subtle. When the patient is assessed for memory in Alzheimer’s disease (AD). Positron emission problems the disease has most probably been ongoing in tomography (PET) amyloid beta (Aβ) tracers such as the brain for several years and has most probably induced Pittsburgh Compound B detect increasing deposition nonrepairable disturbances of important functional of fi brillar Aβ in the brain at the prodromal stages of neuronal networks and loops of the brain. It is a challenge AD, while the levels of fi brillar Aβ appear more stable to test whether some of these changes could be reversed at high levels in clinical AD. There is a need for PET or slowed down with early drug treatment. ligands to visualize smaller forms of Aβ, oligomeric Th e recent progress in AD research has provided new forms, in the brain and to understand how they knowledge for further understanding the pathology interact with synaptic activity and neurodegeneration. processes of AD that precede the onset of clinical disease The infl ammatory markers presently under by many years.
    [Show full text]
  • In Vivo TSPO Signal and Neuroinflammation in Alzheimer's
    cells Review In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease Benjamin B. Tournier 1,2,* , Stergios Tsartsalis 1 , Kelly Ceyzériat 1,3,4 , Valentina Garibotto 3 and Philippe Millet 1,2 1 Division of Adult Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 1205 Geneva, Switzerland; [email protected] (S.T.); [email protected] (K.C.); [email protected] (P.M.) 2 Department of Psychiatry, University of Geneva, 1211 Geneva, Switzerland 3 Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University and Geneva University Hospitals, 1205 Geneva, Switzerland; [email protected] 4 Division of Radiation Oncology, Department of Oncology, University Hospitals of Geneva, 1205 Geneva, Switzerland * Correspondence: [email protected]; Tel.: +41-22-305-5379 Received: 21 July 2020; Accepted: 18 August 2020; Published: 21 August 2020 Abstract: In the last decade, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) in in vivo imaging has attempted to demonstrate the presence of neuroinflammatory reactions by measuring the 18 kDa translocator protein (TSPO) expression in many diseases of the central nervous system. We focus on two pathological conditions for which neuropathological studies have shown the presence of neuroinflammation, which translates in opposite in vivo expression of TSPO. Alzheimer’s disease has been the most widely assessed with more than forty preclinical and clinical studies, showing overall that TSPO is upregulated in this condition, despite differences in the topography of this increase, its time-course and the associated cell types. In the case of schizophrenia, a reduction of TSPO has instead been observed, though the evidence remains scarce and contradictory.
    [Show full text]
  • Local Houses of Worship Local H
    Local Houses of Worship Local Houses of Worship Compliments of UPMC Presbyterian Office of Spiritual Care, Compliments of UPMC Presbyterian Office of Spiritual Care, 412-647-7560 412-647-7560 Downtown Monroeville Chabad at Pitt Friends Meeting House Downtown Monroeville Chabad at Pitt Friends Meeting House 215 Lytton Ave. (Quaker) 215 Lytton Ave. (Quaker) Beth Hamedrash Hagodol/ (outside of city) Beth Hamedrash Hagodol/ (outside of city) 443-525-4212 4836 Ellsworth Ave. 443-525-4212 4836 Ellsworth Ave. Beth Jacob Congregation Beth Jacob Congregation Chabad Jewish Center www.chabadpgh.org 412-683-2669 Chabad Jewish Center www.chabadpgh.org 412-683-2669 (Jewish Orthodox) (Jewish Orthodox) of Monroeville www.quaker.org/legacy/ of Monroeville www.quaker.org/legacy/ 810 5th Ave. 810 5th Ave. (Jewish Hassidic) Church of the Ascension pghpamm (Jewish Hassidic) Church of the Ascension pghpamm 412-471-4443 2715 Mosside Blvd. (ACNA) 412-471-4443 2715 Mosside Blvd. (ACNA) 412-372-1000 4729 N. Ellsworth Ave. Heinz Memorial Chapel 412-372-1000 4729 N. Ellsworth Ave. Heinz Memorial Chapel Trinity Episcopal Cathedral Trinity Episcopal Cathedral www.jewishmonroeville.com 412-621-4361 (non-denominational) www.jewishmonroeville.com 412-621-4361 (non-denominational) 328 Sixth Ave. 328 Sixth Ave. www.Ascensionpgh.org Bellefield Ave. www.Ascensionpgh.org Bellefield Ave. 412-232-6404 412-232-6404 Christ’s Church Ministries between Forbes and Fifth Christ’s Church Ministries between Forbes and Fifth www.trinitycathedralpgh.org www.trinitycathedralpgh.org (Hebraic Christian Fellowship) Church of Christ 412-624-4156 (Hebraic Christian Fellowship) Church of Christ 412-624-4156 1622 James St. (non-denominational) www.heinzchapel.pitt.edu 1622 James St.
    [Show full text]
  • General Orientation Handbook 2019
    GENERAL ORIENTATION HANDBOOK 2019 -Table of Contents- UPMC Horizon: Organizational Review • Business Unit Mission/Vision/Values • AIDET Plus the Promise • UPMC Horizon Senior Leadership Team Organizational Goals Ethics & Code of Conduct • Human Resources Performance Management License/Certification/Registration & Required Clearances (if applicable) Orientation Period Drug Free Workplace Clean Air/Smoke Free Attendance Guidelines Corrective Action & Discharge Grievance Policy Harassment Employee Rights Equal Employment & Non-Discrimination Fair Labor Standard Act LifeSolutions • Employee Health/MyHealth@ Work Worker’s Compensation Work Related Injuries/Illness Environment of Care • Safety Management Safety Officer Safety Management Plan • Security Management Reporting Security Issues Door Access/Sensitive Areas Workplace Violence • Fire Safety & Response/Life Safety • Medical Equipment/Electrical Safety Safe Medical Device Act • Utility Systems • Emergency Preparedness/Disaster Management Code/Condition Definitions • Hazardous Materials/Waste Management Spill Response • Radiation Safety Infection Prevention & Control • OSHA Bloodborne Pathogens • Employee Health Services • Tuberculosis • Hand Hygiene • PPE/Standard & Isolation Precautions Patient Rights and Safety • Reporting Patient Incidences • MCARE • National Patient Safety Goals • Sentinel Events • Abuse & Neglect • New Born Protection/Safe Haven Program • Fall Prevention • Restraints • Privacy & Security • HIPAA/Confidentiality • Patient Rights & Responsibilities • Organizational
    [Show full text]
  • UPMC Sports Medicine Concussion Program Fellowship Opportunities
    UPMC Sports Medicine Concussion Program Fellowship Opportunities Established in 2000, the UPMC Sports Medicine Concussion Program has grown to include seven attending clinical neuropsychologists who work within a multidisciplinary team to assess, diagnose, and treat concussions. This team includes primary care sports medicine, physical medicine and rehabilitation, neurovestibular rehabilitation, neurosurgery, neuro-radiology, behavioral neuro-optometry, and physical therapy, including both musculoskeletal evaluations and sport-specific exertion therapy. In addition to this primary location, there are currently five satellite clinics located throughout the Greater Pittsburgh area including UPMC Lemieux Sports Complex in Cranberry, UPMC Monroeville, UPMC Bethel Park, UPMC Children’s Hospital of Pittsburgh at Pine Township, and UPMC Children’s Hospital of Pittsburgh South in Bridgeville. Clinical Training Model Fellows begin with a one month training intensive working closely with Dr. Collins. Alongside current fellows, new fellows will learn competence with the clinical interview, administration of the vestibular/ocular-motor screening (VOMS), and interpretation of Under the guidance of Michael “Micky” Collins, PhD, clinical computer-based neurocognitive testing, as well as more traditional and executive director, the UPMC Sports Medicine Concussion neuro-psychological evaluation tools. After the first month, fellows Program sees over 17,000 patient visits, involving between will enter into the regular clinical rotation, in which they will work 6,000-7,000 unique patients, each year. The clinical team is in some capacity with all faculty members and rotate amongst involved in the evaluation and management of concussions for the satellite clinics. Fellow offices are located at the UPMC Rooney athletes at all levels of sports participation, including professional, Sports Complex, where all fellows have access to a computer, collegiate, high school, and youth athletes.
    [Show full text]
  • Pittsburgh, PA 15213 412-623-2345
    Pittsburgh, PA 15213 412-623-2345 https://www.upmc.com/locations/hospitals/presbyterian 1 2 Letter from CNO…………………………………………………………………………………………………………………………………………… 1 About UPMC Presbyterian……………………………………………………………………………………………………………………………. 2 Nursing Strategic Plan……………………………………………………………………………………………………………………………………. 3 Magnet Journey Update…………………………………………………………………………………………………………………………………. 4 COVID-19 Caregivers…………………………………………………………………………………………………………………………………….. 5-6 How to Prevent COVID-19……………………………………………………………………………………………………………………………. 7 Linking Living Donors During COVID-19 Crisis…………………………………………………………………………………………… 8 Exemplary Professional Practice…………………………………………………………………………………………………... 9-10 Sustained Achievement of Bedside Shift Report Practices……………………………………………………………………. 9 Improved Compliance with Hourly Rounding………………………………………………………………………………………… 10 Structural Empowerment………………….………………………………………………………………………………………….. 11-21 Nursing Certifications……………………………………………………………………………………………………………………………….. 11 Nursing Degrees………………………………………………………………………………………………………………………………………… 12 Panel Presentations…………………………………………………………………………………………………………………………………… 13 Podium Presentations………………….……………………………………………………………………………………………………………. 13 Poster Presentations…………………………………………………………………………………………………………………………………. 13-14 Leadership Positions in Professional Organizations………………………………………………………………………………. 14 Cameos of Caring Recipients/Nominees………………………………………………………………………………………………... 15 Above and Beyond Recipients………………………………………………………………………………………………………………….. 16 ACES Recipients………………………………………………………………………………………………………………………………………….
    [Show full text]
  • John Innocenti President UPMC Presbyterian Shadyside 200 Lothrop Street - MUH N739 Pittsburgh, PA 15213 Phone: 412-647-5286 [email protected]
    John Innocenti President UPMC Presbyterian Shadyside 200 Lothrop Street - MUH N739 Pittsburgh, PA 15213 Phone: 412-647-5286 [email protected] John Innocenti is the President of UPMC Presbyterian Shadyside Hospital, the flagship of the UPMC System, which comprises 16 hospitals in the Western Pennsylvania area. UPMC Presbyterian Shadyside, which includes UPMC Presbyterian, UPMC Shadyside, UPMC Montefiore, UPMC Eye & Ear Institute and Western Psychiatric Institute and Clinic, is located in the Oakland district of Pittsburgh, and comprises over 1200 MedSurg beds, 220 ICU Beds and 310 psychiatric beds. It is also a Level I Trauma Center, and houses the Thomas Starzl Transplant Institute, which comprises one of the nation’s largest transplant programs. The Shadyside campus includes the Hillman Cancer Center and the Posner Pavilion. Mr. Innocenti has both an Industrial Engineering Degree and MBA from the University of Pittsburgh. He is a member of various boards, including the UPMC Monroeville Surgery Center, Family House, as well as the President of the South Park School Board. Mr. Innocenti was the recipient of the University of Pittsburgh 2005 Distinguished Alumni Award from Industrial Engineering, was named the 2011 Corporate Gift of Life Awardee by the National Kidney Foundation, and the 2013 Arthritis Foundation honoree. Mr. Innocenti was at the University Hospitals of Cleveland, as well as several years of consulting prior to joining Montefiore Hospital in 1976. Montefiore Hospital merged with UPMC in 1990, and Mr. Innocenti has varying levels of administrative responsibilities in his 30 years with the Health System. Mr. Innocenti is also an Adjunct faculty member at the University of Pittsburgh, and has taught management courses for over twenty years.
    [Show full text]
  • UPMC INFUSION SERVICES Why Choose UPMC Infusion Services?
    UPMC INFUSION SERVICES Why Choose UPMC Infusion Services? Locations Near You Therapy times vary based on the treatment. All therapies must be ordered by a UPMC physician. Services are offered throughout the week at multiple locations. To schedule an appointment at a UPMC Outpatient Infusion Center, please contact that individual facility. For more information visit UPMC.com/InfusionCenter. CENTRAL NOrtH Magee-Womens Hospital of UPMC Hamot UPMC Infusion Center 215 Holland St. 300 Halket St., Suite 5600 Erie, PA 16507 Pittsburgh, PA 15203 814-877-6600 412-641-3615 M-F, 7 a.m. to 6:30 p.m. M-F, 7 a.m. to 5 p.m. UPMC Horizon – UPMC Mercy – Southside Greenville 2000 Mary St. 110 N. Main St. Pittsburgh, PA 15203 Greenville, PA 16125 UPMC Infusion Services offers outpatient infusion services 412-488-5290 724-589-6842 M-F, 7 a.m. to 3:30 p.m. M-F, 7 a.m. to 3:30 p.m. to provide patients with a safe and comfortable outpatient setting to receive infusion therapy. UPMC Presbyterian UPMC Horizon – 200 Lothrop St. Shenango Our outpatient infusion centers are staffed by a highly Pittsburgh, PA 2200 Memorial Dr. experienced team of physicians and registered nurses. 412-647-9608 Farrell, PA 16121 Our staff works with referring physicians to provide quality, M-F, 6:30a.m. to 6p.m. 724-983-7021 M-F, 7 a.m. to 3:30 p.m. personalized infusion care to ensure the patient maintains a UPMC Shadyside normal routine with appointments available at convenient 5230 Centre Ave., Fifth Floor UPMC Northwest times as part of an overall continuum of care.
    [Show full text]
  • Shadyside Hospital
    Project Area Master Plan 2014 OAKLAND HOSPITALS 200 Lothrop, Pittsburgh, PA 15213 Submission Date: 11/24/2014 Oakland Hospitals Project Area Master Plan 11/24/2014 TABLE OF CONTENTS I. Master Plan II. Planning Area III. Mission and Objectives IV. Existing Property and Uses V. Institutional Needs VI. Ten Year Development Envelope VII. Twenty-Five Year Development Envelope VIII. Transportation Management Plan IX. Environmental Protection Plan X. Open Space and Pedestrian Circulation Plan XI. Urban Design Guidelines XII. Neighborhood Protection Strategy HARLEY ELLIS DEVEREAUX/Trans Associates 2 Oakland Hospitals Project Area Master Plan 11/24/2014 I. MASTER PLAN Introduction UPMC Presbyterian and Montefiore Hospitals (Oakland), located in the heart of Emergency and Trauma Services Oakland, is an adult medical-surgical referral hospital group and a site of ongoing Endocrine Surgery research and graduate programs in conjunction with the University of Pittsburgh Eye Center School of Medicine. The hospital is a renowned center for organ transplantation, Gastrointestinal Surgery and a recognized leader in cardiology and cardiothoracic surgery, critical care medicine and trauma services, and neurosurgery. UPMC Oakland also is Geriatrics designated as a Level I Regional Resource Trauma Center. Founded in 1893, Inflammatory Bowel Disease UPMC Oakland continues to provide state-of-the-art medical care to patients in the Kidney Disease tri-state area and throughout the world. Liver Cancer Center Minimally Invasive Brain Surgery UPMC Oakland is one hospital with two buildings - UPMC Presbyterian and UPMC Neurological Surgery Montefiore - linked by a pedestrian bridge that crosses over two streets with links to other buildings as well. Staff in both buildings deliver the same high-quality care.
    [Show full text]
  • The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’S Disease—Review of Literature and Interesting Images
    diagnostics Review The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images Subapriya Suppiah 1,2 , Mellanie-Anne Didier 3,4 and Sobhan Vinjamuri 3,* 1 Centre for Diagnostic Nuclear Imaging, University Putra Malaysia, Serdang 43400, Selangor, Malaysia; [email protected] 2 Department of Imaging, Faculty of Medicine and Health Sciences, University Putra Malaysia, Serdang 43400, Selangor, Malaysia 3 The Royal Liverpool and Broadgreen University Hospitals NHS Trusts, Prescot St, Liverpool L7 8XP, UK; [email protected] 4 Section of Nuclear Medicine, Department of Surgery, Radiology, Anaesthesia & Intensive Care, The University Hospital of The West Indies, The University of The West Indies, Mona Campus, Kingston 7, Jamaica * Correspondence: [email protected] Received: 23 May 2019; Accepted: 21 June 2019; Published: 25 June 2019 Abstract: Amyloid imaging using positron emission tomography (PET) has an emerging role in the management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. This review aims to take the readers through the array of various indications for performing amyloid PET imaging in the management of AD, particularly using 18F-labelled radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their limitations and potential improved specificity provided by interpretation done in tandem with genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular information (e.g., cerebral spinal fluid (CSF) amyloid levels).
    [Show full text]